Reducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to action

Insulin

Volumn 3, Issue 3, 2008, Pages 176-184

  Unger, Jeff ^a  

^a Catalina Research Institute California   (United States)

Author keywords

endothelial dysfunction; oxidative stress; postprandial hyperglycemia; type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; PLACEBO; PRAMLINTIDE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDLINE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHYSICIAN; PRIMARY MEDICAL CARE; PUBLICATION; RISK FACTOR; RISK REDUCTION;

EID: 48249094537     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(08)80037-1     Document Type: Article

References (59)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2005. Atlanta, Ga: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services
2. (2005). http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf Updated December 20, 2005. Accessed October 10, 2007
3. Kannel W.B., McGee D.L., and for the Framingham Study. Diabetes and cardiovascular disease. JAMA 241 (1979) 2035-2038
4. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
5. Parsons M.W., Barber P.A., Desmond P.M., et al. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Ann Neurol 52 (2002) 20-28
6. Tuomilehto J., Rastenyte D., Jousilahti P., et al. Diabetes mellitus as a risk factor for death from stroke: Prospective study of the middle-aged Finnish population. Stroke 27 (1996) 210-215
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
8. Unger J. Physiologic insulin replacement therapy. Diabetes Management in Primary Care (2007), Lippincott, Williams and Wilkins, Philadelphia, Pa 192-264
9. Unger J. Amylin, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase IV (DPP-IV) inhibitors as novel treatments for diabetes. Diabetes Management in Primary Care (2007), Lippincott, Williams and Wilkins, Philadelphia, Pa 618-646
10. Schmaderer J., and Unger J. Dietary guidelines for Americans. Female Patient 31 (2006) 34-40
11. Riddle M.C., Rosenstock J., Gerich J., and for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
12. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes: The epidemiological evidence. Diabetologia 44 (2001) 2107-2114
13. Pfeifer M.A., Halter J.B., and Porte Jr. D. Insulin secretion in diabetes mellitus. Am J Med 70 (1981) 579-588
14. Mooradian A.D., and Thurman J.E. Drug therapy of postprandial hyperglycaemia. Drugs 57 (1999) 19-29
15. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005) 1615-1625
16. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr Pract 12 Suppl 1 (2006) 60-62
17. Hirsch I.B., and Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J Diabetes Complications 19 (2005) 178-181
18. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 26 (2003) 1589-1596
19. Assaloni R., Da Ros R., Quagliaro L., et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48 (2005) 1919-1924
20. Bae J.H., Bassenge E., Kim K.B., et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 155 (2001) 517-523
21. Ceriello A. The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus. Diabetes Metab Res Rev 16 (2000) 125-132
22. Fadini G.P., Sartore S., Agostini C., and Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 30 (2007) 1305-1313
23. McGowan T.A., Dunn S.R., Falkner B., and Sharma K. Stimulation of urinary TGF-ß and isoprostanes in response to hyperglycemia in humans. Clin J Am Soc Nephrol 1 (2006) 263-268
24. Ceriello A., Quagliaro L., Catone B., et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25 (2002) 1439-1443
25. Ceriello A., Bortolotti N., Motz E., et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 48 (1999) 1503-1508
26. Ceriello A., Piconi L., Quagliaro L., et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28 (2005) 632-637
27. Esposito K., Giugliano D., Nappo F., Marfella R., and for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219
28. Ceriello A., Cavarape A., Martinelli L., et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med 21 (2004) 171-175
29. Scognamiglio R., Negut C., de Kreutzenberg S.V., et al. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29 (2006) 95-100
30. Kuhlencordt P.J., Gyurko R., Han F., et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase doubleknockout mice. Circulation 104 (2001) 448-454
31. Cosentino F., Hishikawa K., Katusic Z.S., and Lüscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96 (1997) 25-28
32. Thuraisingham R.C., Nott C.A., Dodd S.M., and Yaqoob M.M. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57 (2000) 1968-1972
33. Moriel P., and Abdalla D.S. Nitrotyrosine bound to beta-VLDL-apoproteins: A biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 232 (1997) 332-335
34. Ceriello A., Mercuri F., Quagliaro L., et al. Detection of nitrotyrosine in the diabetic plasma: Evidence of oxidative stress. Diabetologia 44 (2001) 834-838
35. Monnier L., Colette C., Dunseath G.J., and Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
36. Giugliano D., Marfella R., Coppola L., et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95 (1997) 1783-1790
37. Marfella R., Esposito K., Giunta R., et al. Circulating adhesion molecules in humans: A role of hyperglycemia and hyperinsulinemia. Circulation 101 (2000) 2247-2251
38. Esposito K., Nappo F., Marfella R., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 106 (2002) 2067-2072
39. Smith D.A., Irving S.D., Sheldon J., et al. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104 (2001) 746-749
40. Unger J. Screening, diagnosis, and management of diabetes-related complications. Diabetes Management in Primary Care (2007), Lippincott, Williams and Wilkins, Philadelphia, Pa 504-617
41. Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease [published correction appears in Circulation. 2003;108:500]. Circulation 104 (2001) 2673-2678
42. Nappo F., Esposito K., Cioffi M., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. J Am Coll Cardiol 39 (2002) 1145-1150
43. West I.C. Radicals and oxidative stress in diabetes. Diabet Med 17 (2000) 171-180
44. Teno S., Uto Y., Nagashima H., et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 23 (2000) 1401-1406
45. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trials of diabetes and cardiovascular disease [NIH News Web site]
46. http://www.nih.gov/news/health/feb2008/nhlbi-06.htm Accessed March 20, 2008
47. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
48. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 1-68
49. The Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44 (1995) 968-983
50. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
51. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
52. Ceriello A., Kumar S., Piconi L., et al. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30 (2007) 649-654
53. Unger J. Lifestyle interventions for patients with diabetes. Diabetes Management in Primary Care (2007), Lippincott, Williams and Wilkins, Philadelphia, Pa 405-464
54. Liu S., Manson J.E., Buring J.E., et al. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 75 (2002) 492-498
55. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
56. Garg S.K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine [published correction appears in Endocr Pract. 2005;11:145]. Endocr Pract. 11 (2005) 11-17
57. Apidra [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2007
58. http://www.fda.gov/medwatch/safety/2007/Apr_PI/Apidra_PI.pdf Accessed November 5, 2007
59. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88